
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Minaris and LIfT BioSciences collaborate in cell therapy development
LIfT BioSciences wants to start its first-in-human clinical trials with an allogeneic neutrophil progenitor-based cell therapy in first Quartal...

INDUSTRIA BIOTEC 2023 with a broader perspective
At this year's INDUSTRIA BIOTEC – a European industry meeting that took place at the KINDL Centre for Contemporary Art in Berlin at the beginning of...

Macomics licences macrophage modulator to Ono
Whether Macomics Ltd nor Ono Pharmaceuticals Co Ltd disclosed any financial details about the deal under which Ono has the option to licence an...

High blood pressure reprograms immune system
German scientists headed by Suphansa Sawamiphak from MDC Berlin have discovered in a zebrafish and mouse model of salt-induced hypertension that...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...